Most Read News

The outlook for the overall pharma sector for 2023 remains mixed. US generic market continues to be challenging, with high-single-digits to low-double-digits price erosion across companies. Additionally, with USFDA plant inspections picking up, regulatory risk for export-focused companies has increased, with a spate of warning letters/import alerts across plants. Comparatively, the domestic India Pharma Market (IPM) continues to clock a secular 10-11% growth for the industry.

The new core banking system will provide solutions for loans, deposits, international and domestic remittances.

Credit rating limits for bank facilities worth Rs4,500 crore has been reaffirmed at ICRA AA+/ICRA A1+.

The average property rate increased 13.9% year on year.

The 100-year-old company is a major player in the domestic soft drinks market.

TML crosses a landmark milestone for 500,000 connected vehicles on their unified, connected vehicle platform.

On the sectoral front, except pharma stocks, all other sectoral indices are trading in the deep red territory.

It has received the Establishment Inspection Report (EIR).

In a recent meeting with analysts at IIFL Capital Services, management of Altigreen discussed the focus on ownership of key tech (BMS, traction motor, transmission system), developed through extensive customer research and in-house R&D. This should be the moat to offer best value.

The loan agreement is for developing infrastructure in various Indian states, a statement from the finance ministry said.